Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

Weight-Loss Medicine Advertising Caution (UK)

GLP-1 agonists and related weight-loss medicines are among the most regulated drug classes in current UK advertising enforcement. This page explains why and how it shapes our content choices.

Educational research-literacy content only. Not medical advice, not dosing guidance, not sourcing advice, and not a protocol for human or animal use. See our responsible information policy.

The legal position

Under the Human Medicines Regulations 2012 and the Blue Guide, it is unlawful to advertise a prescription-only medicine to the general public. This applies to GLP-1 agonists licensed for weight management (e.g. semaglutide as Wegovy, tirzepatide as Mounjaro for the relevant indication).

What this catches

  • Promotional content naming the medicine and inviting use.
  • Pricing or comparison tables that read as purchase-decision tools.
  • Before/after imagery linked to a specific medicine.
  • Affiliate links to commercial sources of prescription medicines.
  • Implied medical claims framed as “research” about a POM.

How we frame this class

  • We describe trial evidence and mechanism, not consumer benefits.
  • We discuss regulatory status and prescribing context.
  • We do not provide acquisition routes or sourcing notes.
  • We do not generate dose calculators or cycle structures for this class.
  • We do not run before/after content.

Patient access

If a clinician considers a GLP-1 medicine appropriate, prescribing takes place through legitimate UK pharmacy channels. We do not substitute for that judgement.

Why this caution is appropriate even for research-literacy content

Education and promotion are adjacent. The MHRA Blue Guide explicitly addresses borderline cases — pages that are framed as information but function as promotion. To avoid drifting into that zone, we keep framing descriptive, conservative, and non-directive.